Anecortave, a synthetic cortisone, has been shown to have antiangiogenic properties that have been established in multiple experimental models of angiogenesis. Anecortave is under investigation to treat exudative age-related macular degeneration (AMD). Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Anecortave is an active ingredient of these brands:
While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.